Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PREFERENCE: 12-Week Open Label Trial On Olanzapine Orodispersible Tablet Vs. Oral Olanzapine Preference Study

NCT00324051 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00324051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00324051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PREFERENCE: 12-Week Open Label Trial On Olanzapine Orodispersible Tablet Vs. Oral Olanzapine Preference Study
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2006
Completion date
September 30, 2007
Enrollment
284 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia